GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inspire Medical Systems Inc (NYSE:INSP) » Definitions » Debt-to-EBITDA

Inspire Medical Systems (Inspire Medical Systems) Debt-to-EBITDA : 0.39 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Inspire Medical Systems Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Inspire Medical Systems's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.0 Mil. Inspire Medical Systems's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $24.8 Mil. Inspire Medical Systems's annualized EBITDA for the quarter that ended in Dec. 2023 was $64.2 Mil. Inspire Medical Systems's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.39.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Inspire Medical Systems's Debt-to-EBITDA or its related term are showing as below:

INSP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.46   Med: -0.9   Max: -0.22
Current: -1.46

During the past 9 years, the highest Debt-to-EBITDA Ratio of Inspire Medical Systems was -0.22. The lowest was -1.46. And the median was -0.90.

INSP's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs INSP: -1.46

Inspire Medical Systems Debt-to-EBITDA Historical Data

The historical data trend for Inspire Medical Systems's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inspire Medical Systems Debt-to-EBITDA Chart

Inspire Medical Systems Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -0.83 -0.57 -0.88 -0.22 -1.46

Inspire Medical Systems Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 -0.15 -0.53 -0.85 0.39

Competitive Comparison of Inspire Medical Systems's Debt-to-EBITDA

For the Medical Devices subindustry, Inspire Medical Systems's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inspire Medical Systems's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Inspire Medical Systems's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Inspire Medical Systems's Debt-to-EBITDA falls into.



Inspire Medical Systems Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Inspire Medical Systems's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 24.846) / -17.06
=-1.46

Inspire Medical Systems's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 24.846) / 64.228
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Inspire Medical Systems  (NYSE:INSP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Inspire Medical Systems Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Inspire Medical Systems's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Inspire Medical Systems (Inspire Medical Systems) Business Description

Traded in Other Exchanges
Address
5500 Wayzata Boulevard, Suite 1600, Golden Valley, MN, USA, 55416
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Executives
Timothy P. Herbert director, 10 percent owner, officer: CEO and President C/O INSPIRE MEDICAL SYSTEMS, INC., 9700 63RD AVENUE NORTH, SUITE 200, MAPLE GROVE MN 55369
Jerry C Griffin director 887L INDUSTRIAL ROAD, SAN CARLOS CA 94070
Carlton Weatherby officer: Chief Strategy Officer C/O INSPIRE MEDICAL SYSTEMS, INC., 9700 63RD AVENUE NORTH, SUITE 200, MAPLE GROVE MN 55369
Steven Jandrich officer: Chief Comp Off & VP, Human Res C/O INSPIRE MEDICAL SYSTEMS, INC., 9700 63RD AVENUE NORTH, SUITE 200, MAPLE GROVE MN 55369
Philip Ebeling officer: Chief Operating Officer INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BLVD., SUITE 1600, GOLDEN VALLEY MN 55416
John Rondoni officer: Chief Technology Officer C/O INSPIRE MEDICAL SYSTEMS, INC., 9700 63RD AVENUE NORTH, SUITE 200, MAPLE GROVE MN 55369
Richard Buchholz officer: Chief Financial Officer C/O INSPIRE MEDICAL SYSTEMS, INC., 9700 63RD AVENUE NORTH, SUITE 200, MAPLE GROVE MN 55369
Randy Ban officer: Senior VP. & Sales & Marketing C/O INSPIRE MEDICAL SYSTEMS, INC., 9700 63RD AVENUE NORTH, SUITE 200, MAPLE GROVE MN 55369
Marilyn C Nelson director C/O EXXON MOBIL CORP, 5959 LAS COLINAS BLVD., IRVING TX 75039-2298
Cynthia Burks director C/O INSPIRE MEDICAL SYSTEMS, INC., 9700 63RD AVENUE NORTH, SUITE 200, MAPLE GROVE MN 55369
Charisse Y Sparks director C/O INSPIRE MEDICAL SYSTEMS, INC., 9700 63RD AVENUE NORTH, SUITE 200, MAPLE GROVE MN 55369
Georgia Melenikiotou director C/O INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BOULEVARD, SUITE 1600, GOLDEN VALLEY MN 55416
Bryan K Phillips officer: See Remarks 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Shelley G. Broader director 880 CARILLON PARKWAY, ST. PETERSBURG FL 33702
Casey M Tansey director, 10 percent owner 2735 SAND HILL ROAD, MENLO PARK CA 94025

Inspire Medical Systems (Inspire Medical Systems) Headlines

From GuruFocus